这份报告是由和恒咨询发布的《2024年报专精特新上市公司市值战略研究报告》，主要聚焦于专精特新上市公司在市值管理方面的表现和战略建议。以下是 对这份报告的核心内容和重点的解读分析： 1. 专精特新2024年整体情况概览 - 重要历史使命：专精特新企业在中国经济转型中扮演着关键角色，特别是在创新驱动发展、产业升级和产业链安全方面。这些企业被视为中小企业中的领 头羊，具有"专、精、特、新"的属性，是国家创新系统的重要组成部分。 - 指数表现：专精特新指数在过去五年中持续跑赢大盘和中盘，显示出较强的市场表现和较高的估值溢价。截至2025年8月5日，专精特新指数较2021年初上 涨了10.71%，大幅跑赢大盘32.81个百分点、跑赢中盘13.49个百分点。 - 估值与分化：尽管专精特新企业整体估值较高，但内部存在明显分化。部分企业盈利质量高，而部分企业则面临盈利压力。 2. 科学的市值管理战略方法论 - 市值管理的本质：市值管理的核心在于"做价值、涨预期"，即通过价值创造、价值塑造和价值经营来提升企业内在价值，并通过预期传播、预期稳定和预 期释放来增强市场信心。 - 市值管理的三个阶段： - 市值管理诊断：通过分析企 ...

浙江荣泰最新股价为63.50元，较前一交易日上涨0.79%。盘中最高触及64.00元，最低下探61.86元，成 交额达7.79亿元。 该公司主营业务为非金属材料研发生产，涉及人形机器人、专精特新等产业领域。浙江荣泰在投资者互 动平台表示，旗下狄兹精密和金力传动两家子公司经营状况良好，公司将根据订单情况合理安排产能。 8月13日早盘，浙江荣泰曾出现快速反弹，5分钟内涨幅超过2%。当日主力资金净流出6257.33万元，近 五日累计净流出2.45亿元。 风险提示：股市有风险，投资需谨慎。 ...

截至2025年8月13日15时20分，爱朋医疗股价报35.74元，较前一交易日上涨0.65元，涨幅1.85%。当日 开盘价为34.40元，最高触及35.80元，最低下探33.80元，成交量为22.66万手，成交额达7.95亿元。 爱朋医疗属于医疗器械板块，同时涉及机器人概念、专精特新、流感等题材。公司专注于疼痛管理及鼻 腔护理领域，产品包括微电脑注药泵、鼻腔护理喷雾器等。 消息面上，脑机接口概念午后活跃，带动相关个股异动，爱朋医疗盘中一度快速反弹，5分钟内涨幅超 过2%。 资金流向方面，8月13日主力资金净流出205.86万元，近五日累计净流出1.30亿元。 风险提示：股市有风险，投资需谨慎。 来源:金融界 ...

来源：新浪证券-红岸工作室 8月13日，汇隆新材涨2.30%，成交额1.41亿元，换手率7.94%，总市值25.50亿元。 异动分析 跨境电商+一带一路+专精特新+宠物经济 1、2024年12月24日互动易：公司积极利用网络媒体，持续加强与阿里巴巴等国际贸易资讯网站、知名 展会平台的深度合作，推广生产技术和产品信息，不断挖掘国内外潜在客户。 2、公司外贸业务的主要出口国家为印度尼西亚、巴基斯坦、泰国、土耳其等国，多为"一带一路" 沿线 新兴市场。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部国家级专 精特新小巨人企业名单。 4、根据2025年7月3日互动易：近期，公司增资参股杭州宠销社供应链管理有限公司（以下简称"宠销 社"），截至目前，公司持有宠销社2.2%股份，投资金额为600万元，该事项不属于重大交易，不构成 重大资产重组。根据宠销社提供的资料与信息，该公司致力于打造宠物产业数字化基 ...

来源：新浪证券-红岸工作室 8月13日，上海合晶涨14.52%，成交额10.93亿元，换手率12.68%，总市值174.22亿元。 异动分析 专精特新+芯片概念+人民币贬值受益 1、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部国家级专 精特新小巨人企业名单。 2、上海合晶硅材料股份有限公司主要从事半导体硅外延片的研发、生产、销售，并提供其他半导体硅 材料加工服务。公司的主要产品及服务包括半导体硅外延片及其他半导体硅材料加工服务等。公司的核 心产品为8吋及8吋以下外延片，主要用于制备功率器件和模拟芯片等。 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1.59亿，占总成交额的8.47%。 技术面：筹码平均交易成本为19.03元 该股筹码平均交易成本为19.03元，近期该股快速吸筹，短线操作建议关注；目前股价靠近压力位 27.30，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。 公 ...

Core Viewpoint - The company, 美埃(中国)环境科技股份有限公司, is positioned as a leading player in the air purification and environmental governance sector, particularly in the semiconductor industry, with significant growth potential due to its technological advancements and market positioning [2][3]. Company Overview - 美埃科技 specializes in the research, production, and sales of air purification products and atmospheric environmental governance products, with a revenue composition of 88.04% from fan filter units and filter products [7]. - The company was established on June 21, 2001, and went public on November 18, 2022, with a current market capitalization of 6.72 billion [1][7]. Technological Advancements - The company has developed the first domestic 28nm lithography equipment and provides high-standard cleanroom environments, which are crucial for semiconductor manufacturing [2]. - It has been a long-term supplier to 中芯国际, providing essential air purification equipment that meets stringent cleanliness requirements for advanced semiconductor processes [3]. Financial Performance - For the first quarter of 2025, the company reported a revenue of 317 million, representing a year-on-year growth of 16.02%, and a net profit of 41.92 million, up by 18.45% [8][9]. - Cumulative cash dividends since the company's A-share listing amount to 80.64 million [9]. Market Position - 美埃科技 has been recognized as a national-level "specialized, refined, and innovative" small giant, indicating its leading position in the domestic semiconductor cleanroom equipment market [2]. - The company is also a qualified supplier for international semiconductor manufacturers such as Intel and ST Microelectronics, enhancing its competitive edge [2].

来源：新浪证券-红岸工作室 8月13日，腾亚精工涨1.73%，成交额1.93亿元，换手率8.18%，总市值28.42亿元。 异动分析 专精特新+人民币贬值受益+中俄贸易概念 技术面：筹码平均交易成本为18.50元 1、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 2、根据2024年年报，公司海外营收占比为64.88%，受益于人民币贬值。 3、2023年10月16日互动易显示，公司积极响应国家一带一路发展政策，目前主要与俄罗斯等国家有业 务往来，主要为其提供动力工具等相关产品。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入163.12万，占比0.01%，行业排名62/243，连续3日被主力资金增仓；所属行业主力净流 入1.62亿，当前无连续增减仓现象，主力趋势不明显。 区间今日近3日近5日近10日近20日主力 ...

来源：新浪证券-红岸工作室 8月13日，慧智微跌0.48%，成交额3.04亿元，换手率7.43%，总市值58.31亿元。 异动分析 芯片概念+国家大基金持股+5G+人民币贬值受益+专精特新 1、公司主营业务为射频前端芯片及模组的研发、设计和销售。公司具备全套射频前端芯片设计能力和 集成化模组研发能力，技术体系以功率放大器（PA）的设计能力为核心。 2、国家集成电路产业投资基金二期股份有限公司持2603万股，占总股本5.75%. 3、根据公司招股说明书：公司的产品包括5G模组和4G模组，主要应用于手机和物联网领域。 今日主力净流入-2137.97万，占比0.07%，行业排名119/165，该股当前无连续增减仓现象，主力趋势不 明显；所属行业主力净流入-22.36亿，当前无连续增减仓现象，主力趋势不明显。 区间今日近3日近5日近10日近20日主力净流入-2137.97万1735.30万-557.08万-1200.06万-5953.00万 主力持仓 4、根据2024年年报，公司海外营收占比为98.18%，受益于人民币贬值。 5、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 ...

Core Viewpoint - Spring Medical is a leading domestic orthopedic medical device manufacturer focusing on the research, development, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2][3][8]. Group 1: Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021 [7]. - The company's main products include joint prosthetics covering hip, knee, shoulder, and elbow joints, as well as a full range of spinal implant products [8]. - The company has achieved a revenue composition of 99.92% from medical device products and 0.08% from other sources [8]. Group 2: Product Development and Innovation - The company has developed a range of orthopedic products, including hip and knee surgical robots and medical image processing software for surgical planning, indicating its investment in smart medical technology [2]. - Spring Medical is in the design and inspection phase for a customized porous tantalum dental implant product [2]. Group 3: Industry Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the national evaluation of small and medium-sized enterprises [3]. Group 4: Financial Performance - For the period from January to March 2025, Spring Medical reported a revenue of 230 million yuan, representing a year-on-year growth of 3.60%, and a net profit attributable to shareholders of 58.07 million yuan, up 5.20% year-on-year [8]. - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [9]. Group 5: Market Activity - On August 13, the stock price of Spring Medical decreased by 0.04%, with a trading volume of 85.43 million yuan and a turnover rate of 1.20%, resulting in a total market capitalization of 9.616 billion yuan [1]. - The stock has seen a net inflow of 669,900 yuan from major funds today, with a ranking of 29 out of 131 in its industry [4].

Core Viewpoint - The news highlights the performance and business activities of Hangzhou Hemai Electric Power Electronics Co., Ltd., focusing on its growth in the photovoltaic and energy storage sectors, as well as its recent stock movements and shareholder activities. Group 1: Company Overview - Hangzhou Hemai Electric Power Electronics Co., Ltd. specializes in the research, manufacturing, and sales of photovoltaic inverters, energy storage products, and electrical equipment [2][7] - The company's main products include micro-inverters, monitoring equipment, distributed photovoltaic power generation systems, modular inverters, and energy storage systems [2][7] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and technological capabilities [2] Group 2: Financial Performance - As of March 31, the company reported a revenue of 336 million yuan for the first quarter of 2025, representing a year-on-year growth of 1.46%, while the net profit attributable to shareholders was a loss of 10.36 million yuan, a decrease of 115.39% year-on-year [8] - The company's overseas revenue accounted for 64.25% of total revenue, benefiting from the depreciation of the RMB [3] Group 3: Stock Market Activity - On August 13, the company's stock price increased by 2.55%, with a trading volume of 202 million yuan and a turnover rate of 1.46%, bringing the total market capitalization to 13.92 billion yuan [1] - Hangzhou Kaikai Holdings Group announced plans to increase its stake in Hemai, with an investment of no less than 111.5 million yuan and up to 223 million yuan, supported by a special loan from China CITIC Bank [3] Group 4: Technical Analysis - The average trading cost of the company's shares is 108.82 yuan, with the stock price approaching a resistance level of 113.45 yuan, indicating potential for upward movement if the resistance is broken [6]